News & Publications

Stay in the know about our company, science and our aspiration to use gene therapy to restore vision and prevent blindness.

Sort by Date:
Adverum Appoints CMO and CSO
Sort by Date:

Investors

We’re pioneering innovation in the field of gene therapy. For our lead therapy Ixo-vec, we are excited to see the potential for a single intravitreal injection to extend the treatment benefit from weeks to years in patients with wet AMD – even those who may have previously required frequent anti-VEGF injections. Our mission is to establish ocular gene therapy as a new standard of care for debilitating ocular diseases.